A report, by the UK Bioindustry Association, found that venture capital investment in UK biotech companies rose from $178 million in first quarter 2018 to $240 million in first quarter 2019.
The partnership between the US software giant and UK-based biotech company is designed to increase the yield and improve the purity of lentiviral vectors in gene therapy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Financial Times reported Monday that the Japanese drugmaker would merge its UK operations with a Dutch subsidiary.
Many supporters of the UK's withdrawal from the EU say "no deal, no problem," but drugmakers' actions suggest "no deal, big problem."
The studies - in lung and head and neck cancers - produced negative results late last year. Several Phase I Imfinzi and tremelimumab studies were also removed, but others were added to the company's pipeline.
The Swiss drugmaker is concerned that a no-deal Brexit would disrupt delicate supply chains and urged the UK and EU to provide clarity in order to minimize disruptions.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The potential rewards for drugmakers' investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
The British drugmaker plans to separate the consumer health joint venture with Pfizer announced Wednesday three years after the transaction closes.
The company pointed to better survival numbers in patients with high tumor mutational burden, in a presentation at the ESMO immuno-oncology congress in Geneva.
The agreement would have allowed UK pharmaceutical regulations to remain under EMA authority after Brexit. Uncertainty around the planned withdrawal has caused worry in the life sciences sector.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.
In buying the US-based company for a 110 percent premium over its average 30-day share price, GSK hopes to beef up its oncology pipeline.
A number of scenarios could indeed diminish the UK's attractiveness, but it is likely to remain an important player, with a lot riding on the future regulatory regime.
Ian Hudson, CEO of the MHRA, will step down in September 2019. He cited the country's withdrawal from the European Union as a key factor.
The UK would remain subject to EMA regulations during a "transition period" to minimize drug supply disruptions, drawing industry praise. But a trade group was also concerned that a draft political declaration could jeopardize drug safety.